Multicenter Evaluation of a Gradient Diffusion Method for Antimicrobial Susceptibility Testing of *Helicobacter pylori*

© Salika M. Shakir, Joshua Otiso, George Keller, Hillary Van Heule, Lucas J. Osborn, Nicoynn Cole, Audrey N. Schuetz, Sandra S. Richter, Marc Roger Couturier

Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA

Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah, USA

**ABSTRACT** *Helicobacter pylori* is an important human pathogen associated with peptic ulcer disease, dyspepsia, and gastric malignancy. Antimicrobial susceptibility testing (AST) is often requested for patients who fail eradication therapy. The Clinical and Laboratory Standards Institute (CLSI) reference method, agar dilution (AD), is not performed in most laboratories and maintaining organism viability during transit to a reference laboratory is difficult. We assessed the performance of the Etest (bioMérieux) as a method for *H. pylori* AST in comparison to AD. Etest MICs were determined for 83 *H. pylori* isolates at ARUP and Cleveland Clinic (CC). Categorical agreement (CA), very major, major, and minor errors (VME, ME, and mE) were determined for Etest using AD performed at Mayo Clinic Laboratories as the reference method. Testing on isolates with errors was repeated to determine final results summarized below. For clarithromycin, 66.3% of isolates were resistant (R) by AD; Etest results at each laboratory showed 1mE (1.2%) and 1 ME (3.8%). For tetracycline, only 2 isolates were R by AD; a single VME occurred at both sites (98.8% CA, 50% VME) with the same isolate. Applying EUCAST levofloxacin breakpoints to interpret ciprofloxacin results, 60.2% of isolates were R by AD; ARUP CA was 97.6% (1 ME (3%), 1 VME (2%)) and CC CA was 96.3% (1 ME (3%), 2 VMEs (4%)). Despite high error rates, the categorical agreement was acceptable (>90%) for all three antibiotics between AD and Etest. In-house susceptibility testing by gradient diffusion can allow for testing of fastidious organisms that may not survive transport to specialized laboratories; however, the method is not without technical challenges. Characterization of resistance mechanisms, increased AD dilutions, and testing from the same inoculum may determine if the observed errors reflect technical issues or breakpoints that need optimization.

**IMPORTANCE** Routine antimicrobial susceptibility testing (AST) of *Helicobacter pylori* by agar dilution is difficult to perform and not practical in most clinical microbiology laboratories. The Etest gradient diffusion method can be a reliable alternative for *H. pylori* AST with the advantage of being a less laborious quantitative method. This work reveals that an optimized Etest method can provide acceptable performance for *H. pylori* AST and describes the challenges associated with this methodology.

**KEYWORDS** *Helicobacter pylori*, antimicrobial susceptibility, Etest, agar dilution, fastidious isolates organism, method comparison

*Helicobacter pylori* causes gastritis and peptic ulcers as well as chronic, nonresolving infections associated with the development of gastric cancer. Current guidelines by the American College of Gastroenterology (ACG) for the management of *H. pylori* infection recommend that all patients receive eradication therapy to reduce the risk of ulcer...
bleeding. Triple therapy consisting of amoxicillin, a proton pump inhibitor (PPI), and clarithromycin or metronidazole for 14 days is recommended if the rate of antimicrobial resistance is below 15% (1). Quadruple therapy consists of a PPI, bismuth, tetracycline, and metronidazole for 14 days and is indicated for patients with previous macrolide exposure or severe penicillin allergies (1). An increase in *H. pylori* resistance to the standard antibiotics in the triple and quadruple therapies has led to frequent treatment failures (2–4) and as a result of these failures, levofloxacin-based-triple therapy (so called “salvage treatment”) has been advocated after initial success was reported in multiple studies (5–7). Fluoroquinolone resistance in *H. pylori* is also increasing which has decreased the efficacy of this salvage therapy (8). Clinicians caring for patients with treatment failure often submit gastric biopsy specimens to the microbiology laboratory with requests for *H. pylori* culture and susceptibility testing.

The Clinical and Laboratory Standards Institute (CLSI) has approved agar dilution as a “gold standard” reference AST method for *H. pylori* with established MIC breakpoints only for clarithromycin. Breakpoints for additional agents have been published by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Agar dilution testing is only available in a small number of laboratories, and the yield of send-out testing can be significantly hampered due to isolates losing viability in transit or becoming contaminated upon multiple subcultures and manipulations. The Etest (bioMérieux) is an MIC gradient diffusion method that has been described in various *H. pylori* studies to date but there is variability among testing procedures and reported assay performances. The purpose of this multicenter study was to assess the performance of Etest using a procedure optimized by members of the CLSI M45 subcommittee for *H. pylori* AST using agar dilution as the reference method (9, 10).

### RESULTS

An overview of the initial and final (postdiscrepancy analysis) categorical agreement and errors attributed to Etest for each antimicrobial agent by testing center is summarized in Table S1 (S1) and Table 1, respectively. Fig. S2 (A-C) shows the major errors and very major errors for each antimicrobial agent. Results for initial and discrepancy testing are outlined in Table S2.

For clarithromycin (Tables 1 and 2), categorical agreement was 97.6% (81/83) after discrepancy testing with only 1 mE and 1 ME at each laboratory. Essential agreement (within ±1 doubling dilution) of final Etest MICs between laboratories occurred for 55.4% of isolates with clarithromycin (Table 2). Agar dilution results changed for 6 isolates with repeat clarithromycin testing and the final resistance rate was 66.3% (55/83) (Table 1 and Table S2).

For tetracycline (Tables 1 and 3), only 2 isolates (2.4%) were resistant by agar dilution (MIC ≥2 μg/mL). One VME for the same isolate occurred at both laboratories and persisted with repeat testing for a final categorical agreement of 98.8% (82/83). An initial VME at ARUP resolved with repeat testing (Table S2). Essential agreement of final Etest MICs between laboratories was 87.9% for tetracycline (Table 3).

For ciprofloxacin (Tables 1 and 4), agar dilution results interpretive categories changed for 3 isolates with repeat testing for a final resistance rate of 60.2%. The final Etest categorical agreement was 96.4% (80/83) at CC (1 ME, 2 VMEs) and 97.6% (81/83) at ARUP (1 ME, 1 VME). The ME was attributed to an isolate with two subpopulations,

| Antibiotic   | Resistant by agar dilution | Categorical agreement | Minor errors | Major errors | Very major errors | Kappa coefficient | 95% confidence interval | Site          |
|--------------|---------------------------|-----------------------|--------------|--------------|-------------------|------------------|------------------------|---------------|
| Clarithromycin | 66.3% (55/83)              | 97.6% (81/83)         | 1            | 1            | 0                 | 0.96             | 0.9–1.0                | CC, ARUP     |
| Tetracycline  | 2.4% (2/83)               | 98.8% (82/83)         | 0            | 0            | 1                 | 0.66             | 0.04–1.0               | CC, ARUP     |
| Ciprofloxacin | 60.2% (50/83)             | 96.4% (80/83)         | 0            | 1            | 2                 | 0.43             | 0.84–1.0               | CC           |
|              |                           | 97.6% (81/83)         | 0            | 1            | 1                 | 0.95             | 0.88–1.0               | ARUP         |

*Kappa between 0.41 and 0.60: moderate agreement; Kappa between 0.61 and 0.80: substantial agreement; Kappa between 0.81 and 1.00: almost perfect agreement.*

TABLE 1 Final Etest performance for each sites measured as categorical agreement with agar dilution as reference method after discrepant analysis

---

March/April 2022 Volume 10 Issue 2 10.1128/spectrum.02111-21
one that was susceptible (MIC 0.064 μg/mL) and one that was resistant (MIC >1 μg/mL) by the Etest method at both sites (Fig. 1). Three initial VMEs at CC and 1 VME at ARUP resolved with discrepancy testing (Table S2).

**DISCUSSION**

In this study, AST using Etest was compared at two study sites for a collection of previously phenotypically characterized isolates with harmonized testing protocols optimized by multiple members of the original CLSI M45-A3 working group. Etest, compared to agar dilution (AD), provides MIC values in-between 2-fold doubling dilutions, whereas agar dilution typically uses 2-fold doubling dilutions. Due to this disparity, discrepancies can arise in interpretation, particularly at lower MIC values.

**TABLE 2** Clarithromycin MICs determined by Etest and the agar dilution method for 83 *Helicobacter pylori* isolates

| Etest MIC (μg/mL) | Initial ARUP | Repeat ARUP | Initial CC | Repeat CC |
|-------------------|--------------|--------------|------------|-----------|
| ≤0.016            | 9            | 14           | 1          | 1 VME<sup>a</sup> |
| 0.03              | 7            | 6            | 1 mE<sup>b</sup> |
| 0.06              | 4            | 3            |             |
| 0.12              | 1 mE<sup>b</sup> | 1 VME<sup>d</sup> | 1 CA<sup>e</sup> | 1 VME<sup>b</sup> |
| 0.25              | 1 mE<sup>e</sup> | 1 VME<sup>f</sup> |             |            |
| 0.5               | 1 CA<sup>b</sup> | 1 mE<sup>e</sup> | 2 CA<sup>b,h</sup> |          |
| 1                 | 1 ME<sup>e</sup> | 1 mE<sup>c</sup> |            |          |
| 2                 | 3<sup>h</sup> | 1 CA<sup>f</sup> | 3          |          |
| 8                 | 5<sup>i</sup> |             | 3          |          |
| 16                | 1 ME<sup>e</sup> | 5<sup>j</sup> | 3          |          |
| 32                | 6            | 2            | 1 CA<sup>e</sup> |
| 64                | 2            | 1            | 1 CA<sup>g</sup> |
| 128               | 1            | 2            |             |          |
| 256               | 1            | 2            |             |          |
| >256              | 23           |             | 2 CA<sup>d</sup> | 36<sup>d</sup> |

**TABLE 3** Tetracycline MICs determined by Etest and the agar dilution method for 83 *Helicobacter pylori* isolates

| Etest MIC (μg/mL) | Initial ARUP | Repeat ARUP | Initial CC | Repeat CC |
|-------------------|--------------|--------------|------------|-----------|
| ≤0.06             | 14           | 14           | 14         | 9         |
| ≤0.03             | 14           | 11           | 16         |           |
| 0.06              | 14           | 10           |            |           |
| 0.12              | 9            | 9            |            |           |
| 0.25              | 1            | 8            | 1 VME<sup>b</sup> |
| 0.5               | 1 VME<sup>b</sup> | 1 VME<sup>b</sup> | 1 VME<sup>b</sup> |          |
| 1                 | 1 VME<sup>e</sup> | 1         |            |          |
| 2                 | 1 CA<sup>f</sup> | 1           |            |          |

**EUCAST breakpoints of susceptible (S) ≤1 μg/mL & resistant (R) >1 μg/mL were applied to determine very major error (VME), categorical agreement (CA).**

**Initial and repeat VMEs at both laboratories.**

**Initial MIC at ARUP. Repeat Etest MIC increased 1 dilution = CA.**
ity, we observed significant differences between results from the two methods for several isolates tested for the three drugs (Table S1). In addition, as AD employed limited dilutions tested at breakpoint concentrations, we were unable to calculate essential agreement between the two methods and clearly assess the accuracy of Etest. Overall, clarithromycin results correlated well between Etest and AD with results showing 90% categorical agreement before discrepancy resolution, and MICs being within 1 log dilution after discrepancy resolution. Despite the low essential agreement for MIC values across the Etest testing sites and significant error rate, we observed substantial agreement (CA >95%) between Etest sites and AD for clarithromycin and tetracycline as observed by other groups strengthening the potential use of the Etest method for *H. pylori* AST (11, 12).

We observed that majority of the isolates tested in our patient population were resistant to clarithromycin (66.3%) and ciprofloxacin (60.2%). However, this does not reflect the national or regional resistance rates of *H. pylori* in the United States to either clarithromycin or fluoroquinolones which are estimated to be about 21%–30% (13). The higher resistance observed suggests a sampling bias toward patients undergoing esophagogastroduodenoscopy (EGD) and biopsy due to previously failed first and/or second line of therapy. Most (98.8%) of strains in our study tested susceptible to tetracycline by both AD and Etest. This is consistent with the low rates of tetracycline resistance (1–3%) that have been reported for *H. pylori* (14, 15). However, the low number of tetracycline resistant isolates in our study confound the comparison between AD and Etest methods.

One major limitation in our study was that both Etest and the comparative AD test were not performed in the same laboratory with the same inoculum. All isolates for Etest were stored at −80°C prior to testing, however, the age of the colonies and nonequivalent passage number of isolates selected may explain the discrepancy of the study results. The reproducibility between the initial and repeat AD results is also concerning and variability

### Table 4

| Etest MIC (µg/mL) | No. isolates with reference agar dilution MIC (µg/mL) |
|-------------------|------------------------------------------------------|
|                   | Initial ARUP | Repeat ARUP | Initial CC | Repeat CC |
| 0.008             | =1 >2        | =1 >2       | =1 >2     | =1 >2     |
| 0.016             | 4            | 3           | 2         | 0         |
| 0.03              | 7            | 9           | 1         | 0         |
| 0.06              | 12           | 1           | 2         | 1         |
| 0.12              | 6            | 6           | 0         | 0         |
| 0.25              | 2            | 1           | 0         | 0         |
| 0.5               | 1            | 0           | 0         | 0         |
|                   | 2            | 1           | 1         | 1         |
|                   | 3            | 1           | 1         | 1         |
| 8                 | 7            | 1           | 1         | 1         |
| 16                | 2            | 1           | 1         | 1         |
| 32                | 2            | 3           | 0         | 0         |
| >32               | 28           | 1           | 4         | 1         |
|                   | 37           | 1           | 4         | 1         |
|                   | 47           | 1           | 4         | 1         |
|                   | 47           | 1           | 4         | 1         |
|                   | 50           | 1           | 4         | 1         |

---

*EUCAST levofloxacin breakpoints of susceptible (S) ≤1 µg/mL & resistant (R) >1 µg/mL were applied to determine very major (VM) & major errors (ME).*

*aInitial and repeat VMEs at both laboratories.*

*bInitial ME at CC; ME at both laboratories with repeat.*

*cInitial VME at ARUP, CA with repeat.*

*dInitial VME at ARUP; CA with repeat.*

*eInitial VME at CC; CA with repeat.*

*fInitial VME at CC; CA with repeat.*

*gInitial VME at ARUP; CA with repeat.*

*hInitial and repeat VME at CC.*

*iInitial VME at CC; CA with repeat.*

**C A**

---

**H. pylori** Susceptibility Testing by Gradient Diffusion

March/April 2022 Volume 10 Issue 2 10.1128/spectrum.02111-21
in inoculum used for the two methods across the three laboratories may be a factor. A second limitation of the study is the lack of levofloxacin AD results for comparison with Etest. While levofloxacin is used in fluoroquinolone-based therapies, susceptibility rates have been shown to be similar to ciprofloxacin (16). Further studies will be helpful to establish a direct comparison of Etest levofloxacin results with agar dilution.

Our study highlights the challenges and imprecisions when using AD as the gold standard method for H. pylori AST. The phenomenon of heteroresistance, described previously, (17, 18) may also contribute to the discrepancy of the results as independent subpopulations of H. pylori may have varied antibiotic susceptibility with resistant colonies potentially selected on multiple passages. This phenomenon may explain the three discrepancies observed in ciprofloxacin susceptibility testing since mixed populations of resistant and susceptible H. pylori colonies were observed for one isolate with the Etest method.

One of the main challenges for H. pylori AST testing is maintaining the viability of the organism during transport to a commercial laboratory; and preventing contamination of the cultures, both of which can delay antimicrobial susceptibility testing and reporting. Previous European studies demonstrate the ease of adopting Etest as an AST method with good correlation between Etest and agar dilution particularly for clarithromycin and amoxicillin (2, 11, 12, 18–21). However, the methodologies pertaining to different inoculum sizes, types of media used, and duration of incubation varied among different studies. Commercial laboratories lack a standardized testing protocol for H. pylori AST by Etest and rely on the manufacturer instructions for use that are not specific for H. pylori. Studies by Megraud et al. and Glupczynski et al. and our results from developmental studies (data not shown) demonstrate that the ideal testing
conditions include inoculating a 3 McFarland of *H. pylori* uniformly on a sheep-blood supplemented MHA plate (aged ≥2 weeks), and incubation of the *H. pylori* AST cultures at 37°C for 72 h under microaerobic conditions (11, 19). These testing conditions yielded overall high categorical agreement with AD and high method reproducibility between Etest testing sites, supporting the adoption of this methodology by other clinical laboratories.

We did not test metronidazole as several studies have reported poor correlation between agar dilution and Etest and a lack of reproducible results for isolates tested in the same laboratory (18, 19, 22, 23). The Etest method overestimates the rate of metronidazole resistance by 10–20% compared to AD (18). Additionally, CLSI M45-A3 guidelines do not recommended in vitro testing for metronidazole as the resistance determination does not reliably predict treatment failure (9).

In conclusion, the performance of Etest using a standardized method shows substantial agreement with agar dilution for clarithromycin and tetracycline for *H. pylori* AST. A more direct comparison of Etest and agar dilution for levofloxacin is needed to further evaluate the utility of Etest to predict fluoroquinolone activity against *H. pylori*. Although challenging, in-house AST by gradient diffusion can allow results to be generated for fastidious organisms that may perish during transport and facilitate observation of heterogeneity that can be obscured when testing limited concentrations by agar dilution.

MATERIALS AND METHODS

**H. pylori** strains. Frozen stocks of 83 *H. pylori* clinical isolates archived at ARUP Laboratories between 2013 and 2017 were used for the study under a protocol approved by University of Utah IRB. Stock cultures of isolates at ARUP with prior agar dilution results (*n* = 68) reported by Mayo Clinic Laboratories (MCL) were de-identified, prepared in 10% glycerol from the same plate, frozen at −70°C, and distributed to participating clinical microbiology laboratories (ARUP laboratories [ARUP] and Cleveland Clinic [CC]) for susceptibility testing by Etest. An additional 15 isolates without prior agar dilution results were distributed to MCL for susceptibility testing by AD and to ARUP and CC for susceptibility testing by Etest. Investigators performing the Etest method were blinded to the agar dilution results. Prior to testing, isolates were subcultured twice on Brucella agar supplemented with vitamin K and incubated for 72–96 h in a microaerobic atmosphere (10% CO₂, 5% O₂, and 85% N₂) at 37°C until sufficient growth was observed.

**Etest method.** Mueller-Hinton agar with 5% sheep blood plates (150 mm diameter, BD) received at least 2 weeks earlier from the manufacturer were inoculated with a 3 McFarland suspension of the isolate prepared in brain heart infusion broth. Etest strips were applied, and the plates were incubated for 72 h in a GasPak (Becton, Dickinson) or Anaoxomat (Advanced Instruments) system yielding a microaerobic environment (10% CO₂, 5% O₂, and 85% N₂) at 37°C. A maximum of three Etest strips were placed on the surface of the plate to avoid overlaps between the elliptical zones of inhibition. The clinical isolates were tested with Etest strips of clarithromycin (0.016–256 μg/mL), tetracycline (0.016–256 μg/mL), and ciprofloxacin (0.006–32 μg/mL). The MIC was read as the intercept of the elliptical zone of inhibition (including pinpoint colonies within zone of inhibition) with the gradient strip and rounded up to the next 2-fold dilution (fig. S1). *H. pylori* strain ATCC 43504 was tested on each day of testing for quality control.

**Agar dilution method.** Testing of the *H. pylori* isolates was performed using the agar dilution method according to CLSI guidelines (9). Briefly, a saline suspension of a 2 McFarland standard was prepared from a 72-h culture of the isolate. A 3 μl inoculum was spotted on Mueller-Hinton agar with 5% aged sheep blood (≥2-weeks) containing the respective antibiotic (clarithromycin 0.25 μg/mL and 0.5 μg/mL; ciprofloxacin 1 μg/mL and 2 μg/mL; tetracycline 0.06 μg/mL, 1 μg/mL, and 2 μg/mL) using a replicator device. The plates were incubated at 37°C for 72 h in a microaerobic atmosphere. The MICs were read as the lowest antibiotic concentration that completely inhibited visible growth.

**Data and statistical analysis.** Results were interpreted by applying CLSI breakpoints for clarithromycin: susceptible (S), ≤0.25 μg/mL; intermediate (I), 0.5 μg/mL; resistant (R), >0.5 μg/mL. The EUCAST breakpoints for tetracycline (S, ≤1 μg/mL; R >1 μg/mL) were applied. EUCAST breakpoints for ciprofloxacin (S, ≤1 μg/mL; R >1 μg/mL) were applied to ciprofloxacin results, due to lack of CLSI or EUCAST breakpoints for ciprofloxacin and the limited AD concentrations tested. Categorical agreement (CA), very major errors (VME), major errors (ME), minor errors (mE), and Cohen’s kappa were determined for Etest using agar dilution as the reference method. The denominator for VME rate calculation was the number of resistant isolates; the denominator for ME rate was the number of susceptible isolates. Discrepancy analysis was performed by repeating agar dilution and Etest on isolates with VME, ME, and mE errors compared to initial agar dilution results. Frozen stocks of 18 isolates with discordant AD and Etest results were prepared from individual stock cultures, frozen in 10% glycerol, and distributed to the participating laboratories. Isolates at ARUP and CC were tested in duplicate by Etest from the same
inoculum. The repeat agar dilution results served as the comparator for the repeat Etest results. Etest MIC results were same between ARUP and CC and within the two sites for 17 out of 18 isolates.

SUPPLEMENTAL MATERIAL
Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 0.3 MB.

ACKNOWLEDGMENTS
We thank bioMérieux for providing the Etest strips for the study and critical review of the manuscript. We thank Peggy Kohnner for her participation in the study. Labor and other reagents used for the study were covered by internal funds at each institution performing testing.

When employed at Cleveland Clinic SSR received research funding from BD Diagnostics, bioMérieux, Affinity Biosensors, Accelerate, Roche, and Diasorin. S.S.R. was employed as VP, Global Medical Affairs at bioMérieux from August 2019–May 2021. M.R.C. receives spousal income and owns stock in bioMérieux.

REFERENCES
1. Chey WD, Leontiadis GI, Howden CW, Moss SF. 2017. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 112: 212–239. https://doi.org/10.1038/ajg.2016.563.
2. Megraud F, Lehous P. 2007. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 20:280–322. https://doi.org/10.1128/CMR.00033-06.
3. Mentis A, Lehous P, Megraud F. 2015. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter 20 Suppl 1:1–7. https://doi.org/10.1111/hel.12250.

4. Park JY, Dunbar KB, Mitui M, Arnold CA, Lam-Himlin DM, Valasek MA, Thung I, Okwara C, Coss E, Cryer B, Doern CD. 2016. Helicobacter pylori clarithromycin resistance and treatment failure are common in the USA. Dig Dis Sci 61:2373–2380. https://doi.org/10.1007/s10620-016-4091-8.
5. Malfertheiner P, Megraud F, O’Morain CA, Arendt J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ, European H, Study G, European Helicobacter Study Group. 2012. Management of Helicobacter pylori infection—the Maastricht IV/Florence Consensus Report. Gut 61:646–664. https://doi.org/10.1136/gutjnl-2012-302084.

6. Nista EC, Candelli M, Zucco MA, Cremonini F, Ojetti V, Finizio R, Spada C, Cammarota G, Gasbarrini G, Gasbarrini A. 2006. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 101:1985–1990. https://doi.org/10.1111/j.1572-0241.2006.00740.x.

7. Jodłowski TZ, Lam S, Ashby CR, Jr. 2008. Emerging therapies for the treatment of Helicobacter pylori infections. Ann Pharmacother 42:1621–1639. https://doi.org/10.1345/aph.1L234.

8. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A. 2010. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 19:409–414.

9. CLSI. 2016. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria, 3rd edition. CLSI guideline M02A9. Clinical and Laboratory Standards Institute, Wayne, PA.

10. CLSI. 2014. Summary minutes of the CLSI Antimicrobial Susceptibility Testing Subcommittee. Clinical and Laboratory Standards Institute, Wayne, PA.

11. Glupczynski Y, Brouet N, Cantagrel A, Andersen LP, Alarcon T, Lopez-Brea M, Megraud F. 2002. Comparison of the E test and agar dilution method for antimicrobial susceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 21:549–552. https://doi.org/10.1007/s0096-002-0757-6.

12. Hachem CY, Claridge JE, Reddy R, Flamm R, Evans DG, Tanaka SK, Graham DY. 1996. Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole. Diagn Microbiol Infect Dis 24:37–41. https://doi.org/10.1016/S0732-8893(95)00252-9.

13. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. 2018. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology 155:1372–1382. https://doi.org/10.1053/j.gastro.2018.07.007.

14. Hulten KG, Lambert LB, Kafus IN, Graham DY. 2021. National and regional US antibiotic resistance to Helicobacter pylori: lessons from a clinical trial. Gastroenterology 161:342–344. https://doi.org/10.1053/j.gastro.2021.03.045.

15. Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. 2015. Antibiotic resistance of Helicobacter pylori among male United States veterans. Clin Gastroenterol Hepatol 13:1616–1624. https://doi.org/10.1016/j.cgh.2015.02.005.

16. Cuadrado-Lavin A, Salcines-Caviedes JR, Carrascosa MF, Mellado P, Monteaugudo I, Llorca J, Cobo M, Campos MR, Ayestaran B, Fernandez-Pousa A, Gonzalez-Colomina E. 2012. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. J Antimicrob Chemother 67:170–173. https://doi.org/10.1093/jac/dkr410.

17. Mascellino MT, Porowska B, De Angelis M, Oliva A. 2017. Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection. Drug Des Devel Ther 11:2209–2220. https://doi.org/10.2147/DDDT.S136240.

18. Osato MS, Reddy R, Reddy SG, Penland RL, Graham DY. 2001. Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int J Antimicrob Agents 17:39–44. https://doi.org/10.1016/S0924-8599(00)0320-4.

19. Megraud F, Lehn N, Lind T, Bayerdorfer E, O’Morain C, Spiller R, Ungle P, van Zanten SV, Wrangstadh M, Burman CF. 1999. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 43:2747–2752. https://doi.org/10.1128/AAC.43.11.2747.

20. Cederbrant G, Kahlmeter G, Ljungh A. 1993. The E test for antimicrobial susceptibility testing of Helicobacter pylori. J Antimicrob Chemother 31:65–71. https://doi.org/10.1093/jac/31.1.65.

21. Glupczynski Y, Labbe M, Hansen W, Craekaert F, Yousowsky E. 1991. Evaluation of the E test for quantitative antimicrobial susceptibility testing of Helicobacter pylori. J Clin Microbiol 29:2072–2075. https://doi.org/10.1128/JCM.29.9.2072-2075.1991.

22. Best LM, Haldane DJ, Keelan M, Taylor DE, Thomson AB, Loo V, Fallone CA, Lyp P, Small FM, Hunt R, Gaudreau C, Kennedy J, Alfa M, Pelletier R, Veldhuyzen Van Zanten SJ. 2003. Multilaboratory comparison of proficiency in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. Antimicrob Agents Chemother 47:3138–3144. https://doi.org/10.1128/AAC.47.10.3138-3144.2003.

23. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. 2013. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 88:33–45. https://doi.org/10.1159/000350719.